Patents by Inventor Umesh Muchhal

Umesh Muchhal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11945880
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: April 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11859011
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: January 2, 2024
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20230365717
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 16, 2023
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11673972
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: June 13, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20220403049
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: May 4, 2022
    Publication date: December 22, 2022
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • BISPECIFIC AND MONOSPECIFIC ANTIBODIES USING NOVEL ANTI-PD-1 SEQUENCES
    Publication number: 20220204624
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 30, 2022
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 11352442
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20220162343
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: December 3, 2021
    Publication date: May 26, 2022
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Bispecific and monospecific antibodies using novel anti-PD-1 sequences
    Patent number: 11312770
    Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 26, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20220041757
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: October 18, 2021
    Publication date: February 10, 2022
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11225528
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 11111315
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: September 7, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • COMPLEMENT COMPONENT C5 ANTIBODIES
    Publication number: 20210101965
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Application
    Filed: August 24, 2020
    Publication date: April 8, 2021
    Inventors: Peter C. BACIU, Yanbin LIANG, Jason GUU, Matthew BERNETT, Umesh MUCHHAL, John DESJARLAIS
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20210102003
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10913803
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 9, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Heterodimeric antibodies that bind CD3 and tumor antigens
    Patent number: 10889653
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 12, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Complement component C5 antibodies
    Patent number: 10752678
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 25, 2020
    Assignees: ALLERGAN, INC., XENCOR, INC.
    Inventors: Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
    Publication number: 20200199251
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Application
    Filed: October 22, 2019
    Publication date: June 25, 2020
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • Heterodimeric antibodies that bind CD3 and CD38
    Patent number: 10526417
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 7, 2020
    Assignee: XENCOR, INC.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
    Publication number: 20190202938
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 4, 2019
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee